Eloxx Pharmaceuticals, Inc. Contracts & Agreements

Form of Amendment to Stock Option Agreement, dated October 16, 2024 (Filed With SEC on October 17, 2024)

PRE-FUNDED COMMON STOCK PURCHASE WARRANT Eloxx Pharmaceuticals, Inc. (Filed With SEC on November 13, 2023)

COMMON STOCK PURCHASE WARRANT Eloxx Pharmaceuticals, Inc. (Filed With SEC on November 13, 2023)

SCHEDULE OF WARRANT HOLDERS (Filed With SEC on November 13, 2023)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 13, 2023)

Eloxx Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (2018 Equity Incentive Plan) (Filed With SEC on November 13, 2023)

ELOXX PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2018 EQUITY INCENTIVE PLAN) (Filed With SEC on November 13, 2023)

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on November 13, 2023)

THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on November 13, 2023)

Sales Agreement, dated as of May 24, 2023, by and between Eloxx Pharmaceuticals, Inc. and Oppenheimer & Co. Inc (Filed With SEC on May 24, 2023)

First Amendment, dated March 7, 2023, to the Loan and Security Agreement, dated as of September 30, 2021, by and among Hercules Capital, Inc., the Company, Zikani Therapeutics,... (Filed With SEC on May 12, 2023)

Description of Registered Securities (Filed With SEC on March 30, 2022)

Loan and Security Agreement, dated as of September 30, 2021, by and among Hercules Capital, Inc., the Company, Zikani Therapeutics, Inc. and the other parties thereto (Filed With SEC on November 8, 2021)

Sales Agreement, dated as of September 30, 2021, by and between Eloxx Pharmaceuticals, Inc. and SVB Leerink, LLC (Filed With SEC on September 30, 2021)

Agreement and General Release, dated as of July 2, 2021, by and between Neil S. Belloff and Eloxx Pharmaceuticals, Inc (Filed With SEC on July 6, 2021)

Underwriting Agreement, dated May 13, 2021, by and between Eloxx Pharmaceuticals, Inc. and B. Riley Securities, Inc (Filed With SEC on May 18, 2021)

Employment offer letter between Eloxx Pharmaceuticals, Inc. and Gary D Rakers dated March 26, 2021 (Filed With SEC on May 7, 2021)

Lease agreement by and between Zikani Therapeutics, Inc. and ARE-480 Arsenal Street, LLC, dated July 28, 2015 (Filed With SEC on May 7, 2021)

First Amendment to Lease agreement by and between Zikani Therapeutics, Inc. and ARE-480 Arsenal Street, LLC, dated June 30, 2020 (Filed With SEC on May 7, 2021)

Agreement and Plan of Merger, dated April 1, 2021, by and among Eloxx Pharmaceuticals, Inc., Delta Merger Sub Acquisition Corporation and Zikani Therapeutics, Inc (Filed With SEC on April 1, 2021)

Employment Agreement, dated as of April 1, 2021, by and between Sumit Aggarwal and Eloxx Pharmaceuticals, Inc (Filed With SEC on April 1, 2021)

Employment Agreement, dated as of April 1, 2021, by and between Vijay Modur and Eloxx Pharmaceuticals, Inc (Filed With SEC on April 1, 2021)

Separation Agreement and General Release, dated as of April 1, 2021, by and between Gregory C. Williams and Eloxx Pharmaceuticals, Inc (Filed With SEC on April 1, 2021)

Executive Employment Agreement between Eloxx Pharmaceuticals, Inc. and Gregory C. Williams dated as of February 25, 2020 (Filed With SEC on March 6, 2020)

Executive Employment Agreement between Eloxx Pharmaceuticals, Inc. and Neil Belloff dated as of February 25, 2020 (Filed With SEC on March 6, 2020)

Employment offer letter between Eloxx Pharmaceuticals, Inc. and Stephen G. MacDonald dated as of September 24, 2019 (Filed With SEC on March 6, 2020)

Change in Control Severance Benefit Plan (Filed With SEC on November 6, 2019)

Underwriting Agreement by and among Eloxx Pharmaceuticals, Inc., Citigroup Global Markets Inc. and Piper Jaffray & Co., dated June 20, 2019 (Filed With SEC on June 21, 2019)

Underwriting Agreement by and among Eloxx Pharmaceuticals, Inc., Citigroup Global Markets Inc. and Piper Jaffray & Co., dated June 20, 2019 (Filed With SEC on June 20, 2019)

Executive Employment Agreement between Eloxx Pharmaceuticals, Inc. and David Snow dated as of June 18, 2018 (Filed With SEC on March 14, 2019)

Loan and Security Agreement, dated as of January 30, 2019, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P., Eloxx Pharmaceuticals, Inc., and Eloxx... (Filed With SEC on March 14, 2019)

Equity Distribution Agreement, dated November 16, 2018, by and between Eloxx Pharmaceuticals, Inc., Citigroup Global Markets Inc. and Cantor Fitzgerald & Co (Filed With SEC on November 16, 2018)

Form of Restricted Stock Unit Grant Notice for Israeli employees (Filed With SEC on August 10, 2018)

Lease Amendment dated June 21, 2018 (Filed With SEC on June 26, 2018)

Employment Agreement with Dr. Greg Williams dated June 25, 2018 (Filed With SEC on June 26, 2018)

Amendment to Research and License Agreement, by and among Eloxx Pharmaceuticals, Inc., Eloxx Pharmaceuticals Ltd. and Technion Research & Development Foundation Ltd., dated as of... (Filed With SEC on June 14, 2018)

Underwriting Agreement by and among Eloxx Pharmaceuticals, Inc., Citigroup Global Markets Inc. and Piper Jaffray & Co., dated April 25, 2018 (Filed With SEC on April 26, 2018)

Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)

Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)

Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)

Form of Israeli Stock Option Grant Package under the Israeli Sub-Plan under the Eloxx Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on March 30, 2018)

Specimen of Common Stock Certificate (Filed With SEC on March 16, 2018)

Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated August 29, 2013 (Filed With SEC on March 16, 2018)

First Amendment to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated November 26, 2013 (Filed With SEC on March 16, 2018)

Second Amendment to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated January 14, 2014 (Filed With SEC on March 16, 2018)

Third Amendment to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated June 9, 2014 (Filed With SEC on March 16, 2018)

First Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated August 3, 2014 (Filed With SEC on March 16, 2018)

Second Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated January 21, 2015 (Filed With SEC on March 16, 2018)

Third Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated February 9, 2015 (Filed With SEC on March 16, 2018)

Fourth Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated April 29, 2015 (Filed With SEC on March 16, 2018)

Fifth Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated June 2, 2015 (Filed With SEC on March 16, 2018)

Sixth Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated January 11, 2016 (Filed With SEC on March 16, 2018)

Seventh Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated March 6, 2016 (Filed With SEC on March 16, 2018)

Eighth Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated July 16, 2017 (Filed With SEC on March 16, 2018)

Ninth Addendum to Research and License Agreement by and between Technion Research and Development Foundation Ltd. and Eloxx Pharmaceuticals Ltd., dated July 16, 2017 (Filed With SEC on March 16, 2018)

Memorandum of Understanding, dated March 13, 2018, by and between Eloxx Pharmaceuticals, Inc. and Dr. Silvia Noiman (Filed With SEC on March 16, 2018)

Employment Agreement, dated as of March 12, 2018, between Eloxx Pharmaceuticals Inc. and Gregory Weaver (Filed With SEC on March 16, 2018)

Employment Agreement, dated as of March 12, 2018, between Eloxx Pharmaceuticals Inc. and Pedro Huertas (Filed With SEC on March 16, 2018)

Eloxx Pharmaceuticals Share Ownership and Option Plan (2013) (Filed With SEC on March 16, 2018)

Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the Eloxx Pharmaceuticals Share Ownership and Option Plan (2013) (Filed With SEC on March 16, 2018)

Performance Stock Option Grant Notice and Stock Option Agreement (Inducement Grant) between Eloxx Pharmaceuticals, Inc. and Robert E. Ward, dated March 5, 2018 (Filed With SEC on March 16, 2018)

Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (Inducement Grant) between Eloxx Pharmaceuticals, Inc. and Robert E. Ward, dated March 5, 2018 (Filed With SEC on March 16, 2018)

Performance Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (Inducement Grant) between Eloxx Pharmaceuticals, Inc. and Robert E. Ward, dated March 5, 2018 (Filed With SEC on March 16, 2018)

Stock Option Grant Notice and Stock Option Agreement (Inducement Grant) between Eloxx Pharmaceuticals, Inc. and Robert E. Ward, dated March 5, 2018 (Filed With SEC on March 16, 2018)

Lease Agreement by and between Eloxx Pharmaceuticals, Inc. and BP Pay Colony LLC, dated October 26, 2017 (Filed With SEC on March 16, 2018)

Employment Agreement, dated as of December 26, 2017, between Eloxx Pharmaceuticals, Inc. and Robert E. Ward (Filed With SEC on December 27, 2017)

Consulting Agreement, dated December 1, 2014, by and between Eloxx Pharmaceuticals Ltd. and Dr. Silvia Noiman (Filed With SEC on December 22, 2017)

Offer to Gregory Weaver from Eloxx Pharmaceuticals Ltd., dated September 11, 2017 (Filed With SEC on December 22, 2017)

Offer to Pedro Huertas from Eloxx Pharmaceuticals Ltd., dated April 17, 2015 (Filed With SEC on December 22, 2017)

Form of Indemnification Agreement (Filed With SEC on December 22, 2017)

Amendment to Agreement, dated as of November 23, 2017, by and among Sevion Therapeutics, Inc., Sevion Sub, Ltd. and Eloxx Pharmaceuticals Ltd (Filed With SEC on November 29, 2017)

Amendment to Agreement, dated as of August 1, 2017, by and among Sevion Therapeutics, Inc., Sevion Sub, Ltd. and Eloxx Pharmaceuticals Ltd (Filed With SEC on October 13, 2017)

SUBSCRIPTIONAGREEMENT (Filed With SEC on August 3, 2017)

AGREEMENT (Filed With SEC on June 6, 2017)

CONVERTIBLE PROMISSORY NOTE (Filed With SEC on May 22, 2017)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on February 22, 2017)

AMENDED ANDRESTATED CONVERTIBLEPROMISSORY NOTE (Filed With SEC on February 22, 2017)

CONSENTAND WAIVER AGREEMENT (Filed With SEC on February 22, 2017)

PREFERRED STOCK EXCHANGE AGREEMENT (Filed With SEC on February 22, 2017)

SEVION THERAPEUTICS, INC. PROMISSORY NOTE (Filed With SEC on November 14, 2016)

SEVIONTHERAPEUTICS, Inc. AMENDMENTTO ConsultingAgreement (Filed With SEC on May 12, 2016)

FORM OF COMMON STOCK PURCHASE WARRANT SEVION THERAPEUTICS, INC. (Filed With SEC on October 9, 2015)

SENESCO TECHNOLOGIES, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on October 9, 2015)

Nondisclosure,Noncompetition and Invention Assignment Agreement (Filed With SEC on October 9, 2015)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 9, 2015)

SUBSCRIPTIONAGREEMENT (Filed With SEC on October 9, 2015)

SEVION THERAPEUTICS, INC. AMENDMENT NO. 1 TO SUBSCRIPTION AGREEMENT (Filed With SEC on October 9, 2015)

SEVIONTHERAPEUTICS, Inc. ConsultingAgreement (Filed With SEC on May 14, 2015)

SUBLEASE AGREEMENT (Filed With SEC on February 17, 2015)

ConfidentialTreatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentialityrequest. Omissions are... (Filed With SEC on February 17, 2015)

RETENTION AGREEMENT (Filed With SEC on February 17, 2015)

SEVIONTHERAPEUTICS, Inc. ConsultingAgreement (Filed With SEC on February 17, 2015)

RETENTION AGREEMENT (Filed With SEC on December 3, 2014)

SENESCO TECHNOLOGIES, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on September 29, 2014)

ConfidentialTreatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentialityrequest. Omissions are... (Filed With SEC on September 29, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on June 27, 2014)

SERIES A WARRANT AMENDMENT AGREEMENT (Filed With SEC on June 16, 2014)

SERIES FA WARRANT AMENDMENT AGREEMENT (Filed With SEC on June 16, 2014)

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among SENESCO TECHNOLOGIES, INC. SENESCO FAB ACQUISITION CORPORATION and FABRUS, INC. Dated as of May 16, 2014 (Filed With SEC on May 19, 2014)

SERIES FA COMMON STOCK PURCHASE WARRANT SenescoTechnologies, Inc. (Filed With SEC on May 19, 2014)

SERIES FB COMMON STOCK PURCHASE WARRANT SenescoTechnologies, Inc. (Filed With SEC on May 19, 2014)

SERIES FC COMMON STOCK PURCHASE WARRANT SenescoTechnologies, Inc. (Filed With SEC on May 19, 2014)

THIS WARRANTAND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARESUBJECT TO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 4 OF THIS WARRANT (Filed With SEC on May 19, 2014)

SERIES FE COMMON STOCK PURCHASE WARRANT SenescoTechnologies, Inc. (Filed With SEC on May 19, 2014)

RETENTION AGREEMENT (Filed With SEC on May 19, 2014)

REVISEDBUDGET YEAR16 PERIOD:March 1, 2014 – August 31, 2014 (Filed With SEC on May 9, 2014)

SENESCO TECHNOLOGIES, INC. 2008 INCENTIVE COMPENSATION PLAN (As Amended and Restated February 11,2014) ARTICLE ONE GENERAL PROVISIONS (Filed With SEC on May 9, 2014)

AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT SenescoTechnologies, Inc. (Filed With SEC on February 27, 2014)

WARRANT AMENDMENT AGREEMENT (Filed With SEC on February 27, 2014)

COMMON STOCK PURCHASE WARRANT SenescoTechnologies, Inc. (Filed With SEC on December 12, 2013)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on December 12, 2013)

COMMON STOCK PURCHASE WARRANT SenescoTechnologies, Inc. (Filed With SEC on December 6, 2013)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on December 6, 2013)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on October 1, 2013)

Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on September 11, 2013)

Senesco Technologies, Inc. 721 Route 202/206 | Suite 130 | Bridgewater, NJ 08807 p ###-###-#### | f ###-###-#### www.senesco.com (Filed With SEC on September 11, 2013)

WARRANT EXCHANGE AGREEMENT (Filed With SEC on June 25, 2013)

PREFERRED STOCK EXCHANGE AGREEMENT (Filed With SEC on June 25, 2013)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on May 9, 2013)

Chardan Capital Markets, LLC 17 State Street, Suite 1600 New York, New York 10004 (Filed With SEC on May 9, 2013)

WARRANT EXCHANGE AGREEMENT (Filed With SEC on May 1, 2013)

COMMON STOCK PURCHASE WARRANT SENESCoTECHNOLOGIES, INC. (Filed With SEC on January 4, 2013)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on January 4, 2013)

Senesco Technologies, Inc. Retention Policy for Officers12 (Adopted by the Board on [____]) (Filed With SEC on October 15, 2012)

AMENDMENT TO RESEARCHAGREEMENT (Filed With SEC on September 28, 2012)

WARRANT EXCHANGE AGREEMENT (Filed With SEC on August 10, 2012)

BIOFUELS EVALUATION AND LICENSE AGREEMENT (Filed With SEC on May 14, 2012)

Senesco Technologies, Inc. Common Stock Purchase Warrant (Void after [ ]) (Filed With SEC on March 2, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 2, 2012)

Confidential Treatment has been requestedfor portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions... (Filed With SEC on February 14, 2012)

Senesco Technologies, Inc. Common Stock Purchase Warrant (Void after Janaury [__], 2017) (Filed With SEC on January 9, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on January 9, 2012)

PROMISSORY NOTE (Filed With SEC on May 13, 2011)

SENESCOTECHNOLOGIES, INC. CommonStock (parvalue $0.01 per share) AtMarket Issuance Sales Agreement (Filed With SEC on December 22, 2010)

SENESCOTECHNOLOGIES, INC. 2008 INCENTIVE COMPENSATIONPLAN (AsAmended and Restated May 25, 2010) ARTICLEONE GENERALPROVISIONS (Filed With SEC on May 28, 2010)

SENESCOTECHNOLOGIES, INC. INDEMNIFICATIONAGREEMENT (Filed With SEC on May 25, 2010)

Nondisclosure,Noncompetition and InventionAssignment Agreement (Filed With SEC on May 25, 2010)

COMMONSTOCK PURCHASE WARRANT SENESCOTECHNOLOGIES, INC. (Filed With SEC on March 29, 2010)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on March 29, 2010)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on March 29, 2010)

[End of text.] (Filed With SEC on March 5, 2010)

CONFIDENTIAL SEPARATIONAGREEMENT AND GENERAL RELEASE (Filed With SEC on February 4, 2010)

CONFIDENTIAL SEPARATIONAGREEMENT AND GENERAL RELEASE (Filed With SEC on November 25, 2009)

SENESCOTECHNOLOGIES, INC. STOCK OPTIONAGREEMENT (Filed With SEC on November 16, 2009)

SENESCOTECHNOLOGIES, INC. RESTRICTEDSTOCK UNIT ISSUANCE AGREEMENT (Filed With SEC on November 16, 2009)

SENESCOTECHNOLOGIES, INC. INDEMNIFICATIONAGREEMENT (Filed With SEC on September 28, 2009)

THISWARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISEARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THISWARRANT (Filed With SEC on July 30, 2009)

THISWARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISEARE SUBJECT TO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 4 OF THISWARRANT (Filed With SEC on July 30, 2009)

THISWARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS (Filed With SEC on July 30, 2009)

THISWARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISEARE SUBJECT TO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 4 OF THISWARRANT (Filed With SEC on July 30, 2009)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 30, 2009)

EXHIBIT10.2 SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 30, 2009)

THISWARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS (Filed With SEC on July 10, 2009)

THISWARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISEARE SUBJECT TO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 4 OF THISWARRANT (Filed With SEC on July 10, 2009)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 10, 2009)

SENESCO TECHNOLOGIES, INC. 2008 INCENTIVECOMPENSATION PLAN (Filed With SEC on February 17, 2009)

Proposal for manufactureand supply of cGMP Polyribonucleotide Duplex for Phase - I Clinical Trials (Filed With SEC on November 14, 2008)

Proposal for Biodistribution and Repeat DoseToxicity Studies in Mice Submitted by: BioReliance 14920 Broschart Road Rockville, MD 20850 To: Cato Research Ltd. and Senesco... (Filed With SEC on November 14, 2008)

KBI BioPharma, Inc. Services Agreement (Filed With SEC on November 14, 2008)

PLACEMENTAGENT WARRANT (Filed With SEC on September 26, 2008)

Confidential Treatment Requested under 17C.F.R. 200.80(b)(4) and240.24b-2 (Filed With SEC on September 26, 2008)

SUPPLY AGREEMENT (Filed With SEC on September 26, 2008)

SECURITY AGREEMENT (Filed With SEC on September 26, 2008)

AMENDMENT NO. 1 TO FINANCIAL ADVISORY AGREEMENT (Filed With SEC on February 14, 2008)

LICENSEAGREEMENT between BAYER CROPSCIENCE AG and SENESCOTECHNOLOGIES, INC. (Filed With SEC on November 14, 2007)

ConfidentialTreatment has been requested for portions of this exhibit. The copy filedherewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on November 14, 2007)

Confidential Treatment has been requested forportions of this exhibit. The copy filed herewith omits the information subjectto the confidentiality request. Omissions are... (Filed With SEC on November 14, 2007)

WARRANT SeriesA (Filed With SEC on September 28, 2007)

SENESCO TECHNOLOGIES, INC. SECURED CONVERTIBLE DEBENTURE (Filed With SEC on September 28, 2007)

WARRANT SeriesB (Filed With SEC on September 28, 2007)

SENESCOTECHNOLOGIES, INC. INDEMNIFICATIONAGREEMENT (Filed With SEC on September 28, 2007)

[INSERT H.C.WAINWRIGHT LETTERHEAD] (Filed With SEC on September 28, 2007)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on September 28, 2007)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 28, 2007)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on September 28, 2007)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on September 28, 2007)

SECURITY AGREEMENT (Filed With SEC on September 28, 2007)

COMMERCIAL LICENSE AGREEMENT (Filed With SEC on February 14, 2007)

LICENSE AGREEMENT between BAYER CROPSCIENCE GmbH and SENESCO TECHNOLOGIES, INC. (Filed With SEC on February 14, 2007)

STANFORD GROUPCOMPANY (Filed With SEC on October 13, 2006)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on October 13, 2006)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on October 13, 2006)

THIS WARRANT AND THE SHARES OFCOMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on October 13, 2006)

H. C .WAINWRIGHT &CO., lNC. Investments Since 1868 (Filed With SEC on October 13, 2006)

SENESCO TECHNOLOGIES, INC. WARRANT TO PURCHASE COMMONSTOCK (Filed With SEC on October 13, 2006)

THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUEDUPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THISWARRANT (Filed With SEC on May 5, 2005)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on May 5, 2005)

Placement Agent Agreement (Filed With SEC on May 5, 2005)

Category

Industry

Companies

Contracts

Eloxx Pharmaceuticals, Inc. Contracts & Agreements